Precigen CEO and leadership

Dr. Christopher Rogers serves as CEO, Chief Science Officer, and is a co-founder of Exemplar Genetics (now Precigen Exemplar). Dr. Rogers is internationally recognized as a leader in the development of porcine disease models, with many research papers, reviews, and patents to his name. Dr. Rogers received his PhD in Pharmacology from Vanderbilt University focusing on gene therapy and his postdoctoral training at the University of Iowa where he and colleagues created the first knockout and knockin models of a human disease in a large animal species - cystic fibrosis in pigs. This work led to the founding of Exemplar Genetics.

Dr. Reed is a molecular geneticist with over twenty years of experience in recombinant DNA technology. He has developed sophisticated transgenic model systems for studying the role of gene products in neuronal, cardiovascular, and cancer systems. Dr. Reed has published numerous peer-reviewed articles in the fields of subcellular modulation, gene regulation and cardiac function and is an inventor on numerous patents. Dr. Reed co-founded Intrexon in 1998 and continues to serve on the Board of Directors. Dr. Reed received his B.S. in Genetics from the University of California-Davis and then completed his M.S. at Wright State University in Biological Science. Dr. Reed received his Ph.D. from the University of Cincinnati in Molecular and Developmental Biology.

Mr. Lehr has broad experience in the areas of corporate, securities, and general business law. Prior to joining Intrexon, he was at Hogan Lovells LLP (previously Hogan & Hartson, L.L.P.) in Baltimore, Maryland. While at Hogan, his practice included the representation of privately and publicly held corporations across many industries, including biotechnology, pharmaceuticals, healthcare, software, technology, and manufacturing. Prior to his time at Hogan, Mr. Lehr served as a judicial clerk for the Honorable Irma S. Raker of the Court of Appeals of Maryland. Mr. Lehr received a B.A. from Swarthmore College, completed post graduate study in Political Science at Johns Hopkins University, and received his J.D. from the University of Maryland School of Law.

Mr. Harry Thomasian Jr. serves as the Chief Financial Officer for Precigen. Mr. Thomasian is a global finance leader with over 35 years of international business experience in equity and debt financings, P&L management and business operations, regulatory compliance and generally accepted accounting principles, SEC filings and Sarbanes-Oxley compliance. Prior to joining the company, Mr. Thomasian was with EY (formerly Ernst & Young LLP), one of the world’s largest global professional services firms. He most recently served as Senior Client Services Partner and the Baltimore Office Growth Markets Leader for the life sciences industry and Senior Partner in EY’s Capital Markets Center in Tokyo as well as other various global, area and local leadership positions. Mr. Thomasian earned a BS in Accountancy from Bentley University and completed the Ernst & Young Executive Development Program at the Kellogg School of Management, Northwestern University. Mr. Thomasian is licensed as a certified public accountant by the State Boards of Accountancy in Maryland, North Carolina, Washington, DC and Virginia.

Dr. Christopher Rogers serves as CEO, Chief Science Officer, and is a co-founder of Exemplar Genetics (now Precigen Exemplar). Dr. Rogers is internationally recognized as a leader in the development of porcine disease models, with many research papers, reviews, and patents to his name. Dr. Rogers received his PhD in Pharmacology from Vanderbilt University focusing on gene therapy and his postdoctoral training at the University of Iowa where he and colleagues created the first knockout and knockin models of a human disease in a large animal species - cystic fibrosis in pigs. This work led to the founding of Exemplar Genetics.

Dr. Reed is a molecular geneticist with over twenty years of experience in recombinant DNA technology. He has developed sophisticated transgenic model systems for studying the role of gene products in neuronal, cardiovascular, and cancer systems. Dr. Reed has published numerous peer-reviewed articles in the fields of subcellular modulation, gene regulation and cardiac function and is an inventor on numerous patents. Dr. Reed co-founded Intrexon in 1998 and continues to serve on the Board of Directors. Dr. Reed received his B.S. in Genetics from the University of California-Davis and then completed his M.S. at Wright State University in Biological Science. Dr. Reed received his Ph.D. from the University of Cincinnati in Molecular and Developmental Biology.